Phase I Dose Escalation Study of Gemcitabine plus Irinotecan in Advanced Solid Tumors

AIM: To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination. PATIENTS AND METHODS: Thirty-nine evaluable patients with advanced solid tumors were treated with gemcitabine (Gem) and irinotecan (Iri) on days 1,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dugan, Elizabeth, Truax, Roxanne, Meadows, Kellen L., Blobe, Gerard C., Morse, Michael A., Fernando, Nishan H., Gockerman, Jon P., Petros, William P., Hurwitz, Herbert I.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4103184/
https://ncbi.nlm.nih.gov/pubmed/20044630
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars